Key Points
- CEO Michael Thomas Henderson sold 20,000 shares on Dec. 10 at $75.38 for $1,507,600, cutting his position by 1.62% and leaving him with 1,212,987 shares valued at about $91.43M.
- That sale is part of recent insider activity (40,000 shares on Dec. 4 and 20,000 on Nov. 13), totaling 80,000 shares sold recently for roughly $5.77M.
- APGE trades near its 52‑week high (opened $77.08, 52‑week high $78.12) with a $5.27B market cap, ~79% institutional ownership, and a MarketBeat consensus rating of "Moderate Buy" with a $98.89 price target.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $75.38, for a total value of $1,507,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,212,987 shares of the company's stock, valued at approximately $91,434,960.06. The trade was a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Michael Thomas Henderson also recently made the following trade(s):
- On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.01, for a total transaction of $3,000,400.00.
- On Thursday, November 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $63.01, for a total transaction of $1,260,200.00.
Apogee Therapeutics Stock Up 0.7%
Shares of APGE opened at $77.08 on Friday. The firm has a market capitalization of $5.27 billion, a PE ratio of -17.60 and a beta of 1.41. The firm has a 50-day moving average price of $61.23 and a 200 day moving average price of $46.69. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $78.12.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. On average, equities analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.
Hedge Funds Weigh In On Apogee Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Lisanti Capital Growth LLC acquired a new position in Apogee Therapeutics in the 2nd quarter worth approximately $800,000. Fox Run Management L.L.C. acquired a new stake in Apogee Therapeutics during the 2nd quarter valued at $437,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Apogee Therapeutics in the second quarter valued at $218,000. Prudential Financial Inc. boosted its position in shares of Apogee Therapeutics by 176.4% in the second quarter. Prudential Financial Inc. now owns 68,845 shares of the company's stock worth $2,990,000 after buying an additional 43,940 shares during the period. Finally, Schroder Investment Management Group grew its holdings in shares of Apogee Therapeutics by 22.9% during the second quarter. Schroder Investment Management Group now owns 119,246 shares of the company's stock valued at $5,179,000 after buying an additional 22,254 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on APGE shares. Deutsche Bank Aktiengesellschaft assumed coverage on Apogee Therapeutics in a research report on Tuesday. They set a "buy" rating and a $103.00 price target on the stock. BTIG Research reaffirmed a "buy" rating and set a $115.00 target price on shares of Apogee Therapeutics in a report on Thursday, October 9th. Royal Bank Of Canada boosted their price target on shares of Apogee Therapeutics from $60.00 to $70.00 and gave the stock an "outperform" rating in a research report on Monday, November 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Apogee Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Apogee Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.89.
View Our Latest Stock Analysis on APGE
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
